Background: There is conflict in the literature about the extent of alterations of resting energy expenditure (REE) in persons with HIV. Objective: The study was conducted to ascertain the mean difference in REE (in kJ) per kilogram of fat-free mass (FFM; REE/FFM) between HIV-positive subjects and control subjects and to investigate heterogeneity in the literature. Design: A meta-analysis comparing classical and Bayesian methods was conducted. Heterogeneity was investigated by using subgroup analysis, metaregression, and a mixed indirect comparison. Results: Of 58 studies meeting the inclusion criteria, 32 included both HIV-positive and control groups; 24 of these 32 were included. Thirty-seven studies were used in the mixed indirect comparison, and 30 were used in the subgroup comparisons of the HIVsymptomatic, lipodystrophy, weight-losing, and weight-stable subgroups and the healthy (HIV-negative) control group. Mean REE/ FFM was significantly higher in 732 HIV-positive subjects than in 340 control subjects [11.93 kJ/kg (95% CI: 8.44,15.43 kJ/kg) and 12.47 kJ/kg (95% CI: 8.19,16.57 kJ/kg), classical and Bayesian random effects, respectively]; the test for heterogeneity was significant (P 0.001). Both the mixed indirect comparison and the subgroup analysis indicated that REE/FFM was highest in the symptomatic subgroup; however, the small number of studies investigating symptomatic subjects limited statistical comparisons. The presence of lipodystrophy, use of highly active antiretroviral therapy, subject age, and method of body-composition measurement could not explain the heterogeneity in the data with the use of metaregression. Conclusions: REE/FFM (kJ/kg) is significantly higher in HIVpositive subjects than in healthy control subjects. Symptomatic HIV infection may contribute to the variations reported in the literature.
INTRODUCTION
Controversy surrounds the role of resting energy expenditure (REE) in HIV-related metabolic abnormalities such as wasting and lipodystrophy syndrome. Early in the HIV pandemic, it was proposed that REE may be elevated in persons with HIV, because it was thought that neither malabsorption or decreased energy intake alone nor both together could explain the weight loss that was characteristic of untreated infection (1) . In noninfective malabsorption, malnutrition, or underfeeding, an appropriate metabolic response is a compensatory drop in REE to preserve the fat-free mass (FFM) (2) . The first 2 published reports were conflicting; Kotler et al (3) reported significantly lower REE/kg FFM in HIV-positive subjects than in healthy control subjects, whereas Hommes et al (4) reported significantly higher REE adjusted for FFM in HIV-positive subjects than in healthy control subjects. The literature published since those initial reports is difficult to summarize informally, because different authors have presented the results by using different summary statistics and different population subgroups, and because methods of measuring body composition vary in the studies. Because FFM is the primary determinant of REE, accounting for 70 -80% of the variation in REE in healthy subjects (5) , comparisons between studies must investigate whether the use of reference or field methods of body-composition measurement explains some of the discrepancies in the results.
Since the widespread introduction of highly active antiretroviral therapy (HAART) in westernized countries in 1996, a new metabolic abnormality, lipodystrophy, has been described (6); its etiology remains unknown, but the syndrome is usually associated with the use of HAART, particularly the protease inhibitor class of drugs but also the nucleoside analogue reverse transcriptase inhibitors (7) . More recently, there have been conflicting reports about the differences in REE between HIV-positive subjects with and without lipodystrophy syndrome (8, 9) .
Clinically, it is of value to establish whether REE is indeed elevated in HIV-positive persons (or in subsets of the HIVpositive population) so that appropriate nutritional advice on the necessary energy intake to achieve the desirable weight can be provided. An integration of the currently available literature is necessary to provide this clinical information.
The primary aim of this study was, by conducting a metaanalysis combining previous research, to ascertain an overall mean difference in REE between HIV-positive subjects and healthy control subjects. Two secondary aims of this study were to investigate variations in this mean difference between various clinical subgroups (eg, persons with lipodystrophy, those who are losing weight, those who are symptomatic, and those who are weight stable) and to investigate the effect of potential confounding covariates on that mean difference. A priori, these covariates were the presence or absence of lipodystrophy in the HIVpositive group, the choice of method of body-composition measurement, the use of HAART in the HIV-positive group, and the mean age of the subjects. In addition, because of the rapidly increasing popularity of the Bayesian framework over classical analysis, which results from the Bayesian framework's allowing the incorporation of external evidence and accounting for all sources of variability (10) , both types of analysis were reported.
MATERIALS AND METHODS

Search strategy and identification of reports
A database search of Medline, CINAHL, Current Contents Connect, HIV/AIDS database, and Expanded Academic Index (from 1981, when AIDS was first described, to September 2004) was conducted by using the search terms "resting energy expenditure and HIV," "resting metabolic rate and HIV," "indirect calorimetry and HIV," and "fat oxidation and HIV." Identified articles were then searched to ascertain whether they met the following inclusion criteria: 1) the studies were conducted in humans; 2) the subjects were adults; 3) the subjects were measured after an overnight fast or under a strict postprandial protocol (because diet-induced thermogenesis has been shown to be prolonged past 300 min in HIV-positive subjects) (11); and 4) data on body composition were collected.
Only studies published in English were considered. The references of the articles identified were also searched, and authors were contacted to identify additional publications.
Data analysis
Crude, classical, and Bayesian methods of meta-analaysis were performed for comparison and to maximize the use of the available data. To use all of the available data comparing HIVpositive subjects and healthy control subjects when estimates of variance were not provided, crude meta-analysis based on the method of Gotzsche (12) was performed. This technique, in which the mean REE of each group is divided by the mean FFM of each group, and that value is then used to calculate an overall mean difference and 95% CIs, has been used previously in a similar meta-analysis (13) .
A traditional meta-analysis, in the classical framework, comparing REE divided by FFM (kJ/kg) in the HIV-positive and control groups and within the HIV subgroups, was performed. The random-effects model based on the method-of-moments estimator as proposed by DerSimonian and Laird (14) was used, with the inverse-variance fixed-effects model shown for comparison; algebraic descriptions of these models are available elsewhere (15, 16) . These analyses were performed by using the METAN (17) command in STATA software (version 7.0; Stata Corporation, College Station, TX).
A Bayesian random-effects method was also used to estimate the common effect and the between-study variance (
2 ) and to compare this estimate with the estimates obtained by using the method of DerSimonian and Laird (18) . Here, too, the Bayesian fixed model is shown for comparison. Classical (or frequentist) methods of statistics assume that each study (in the current case, this meta-analysis) is one in a long-running series of experiments in which the current study estimate (the overall mean difference) is likely to lie within the stated CIs 95% of the time. This differs from the Bayesian approach, in which the study estimate (the overall mean difference) has a probability distribution that expresses our prior belief (prior distribution) about the mean combined with the available data (likelihood) (19) . Two prior distributions were used: a noninformative prior distribution and an informative prior distribution calculated by using the data provided from the single-arm HIV studies. Single-arm studies can be incorporated into a Bayesian analysis in the form of a prior distribution, which allows for the use of these data (15) . The ability to incorporate external information, such as previous research, by using an informed prior distribution (10) is an advantage of the Bayesian technique. To ascertain the effect size and variance for these single-arm estimates, a bootstrap resampling procedure was used to generate control samples with replacement from the pooled data of the available individual studies. In all Bayesian models, the likelihood was initially assumed to be from a normal distribution, the prior distribution for the mean difference was also assumed to be normally distributed, and the prior distribution for the heterogeneity term in the randomeffects models was assumed to be a conjugate gamma distribution, because this is computationally convenient and because it provides the effect estimate (posterior distribution) in the same form as the likelihood (normal distribution) (18) . The choice of gamma prior distributions for the heterogeneity term was tested by comparing the results with those obtained by using a uniform distribution on (20) . Random-effects models with the likelihood that the mean difference between the studies would be coming from a Student's t distribution with the noninformative prior distributions were also evaluated for comparison and to test the assumption of normality of the mean difference estimate. A model with 4 df and a model with the df modeled as an additional unknown parameter are presented (21, 22) .
A mixed indirect comparison was performed in the Bayesian framework on the basis of the method proposed by Spiegelhalter et al (20) . This model allows the incorporation of all available information regardless of whether there are data for all comparisons. The model is set up to compare the HIV subgroups (ie, lipodystrophy, weight-losing, weight-stable, and symptomatic) with healthy control subjects, and within-group comparisons are also modeled.
All Bayesian models were performed by using WINBUGS software (version 1.4; Imperial College & Medical Research Council, Cambridge UK, 2003). A burn-in period of 5000 iterations was used for all models, and the subsequent 5000 iterations were used to estimate the variables of interest. Diagnostic procedures including inspection of autocorrelation plots and trace histories were performed to verify the results. WINBUGS employs a simulation-based Gibbs sampling technique, which is a type of Markov chain Monte Carlo method (10) .
An ancillary analysis was performed on the available individual data to obtain an estimate of REE adjusted for FFM (23) . This analysis was conducted by using the general linear model (analysis of covariance) in SPSS for WINDOWS software (version 11.5.0; SPSS Inc, Chicago, IL). Two models were employed: an analysis with HIV-positive or healthy control subjects as the factor and an analysis considering the study site in addition to HIV status of the subject.
HIV REE META-ANALYSIS
Assessment and exploration of heterogeneity
Heterogeneity was detected by visual inspection and by using the chi-square test and was quantified by calculating the I 2 statistic by the equation
where Q is the heterogeneity statistic, and where df (24) reflects the percentage of the variability between studies that can be attributed to heterogeneity rather than to sampling error (24) . Heterogeneity was initially investigated by considering the factors identified a priori as potential confounders in establishing a common effect. Subgroup analyses were used to visually assess differences between groups, and a more rigorous investigation was provided by the mixed indirect comparison model. Formal investigation of heterogeneity was performed by univariate metaregression with lipodystrophy, technique of body-composition measurement, use of HAART in the HIV-positive group, and mean age of subjects as covariates. A random-effects model based on a restricted maximum likelihood estimate was used, and analyses were performed by using the METAREG (25) command in STATA software. Bayesian metaregression was also conducted with both normal and t distributions for the likelihood of the mean differences between the studies.
Publication bias
Publication bias was assessed visually by using a funnel plot (26) that plots sample size against the treatment effect and that has a funnel shape when publication bias is not present. Formal testing for publication bias was conducted by using the rank correlation test of Begg and Mazumdar (27) , the regression test of Egger et al (28) , and the "trim and fill" method of Duval and Tweedie (29) , a nonparametric method that estimates the number of missing studies along with their mean Ȁ SE difference and then adds in the estimated values, recalculating the overall mean Ȁ SE. Because of the limited number of studies in the subanalyses, these tests are performed only on the primary sample estimates.
Sensitivity analysis
Several sensitivity analyses were conducted on the primary analysis. First, the presentation and comparison of the fixed effects as well as the random-effects analysis are regarded as a sensitivity analysis (15) . The fixed-effect model makes the assumptions that there is no between-study variation and that all the studies are estimating a single underlying effect (10) . In the random-effects model, the incorporation of the heterogeneity parameter (
2 ) allows the assumption that the studies are estimating different underlying effect sizes (15) . Statistically, the decision to use the random-effects model is based on the significance of the test for heterogeneity, but both models should produce a similar overall estimate.
Second, it was important to ascertain whether the studies not reporting REE/FFM were in some way affecting the estimate of the effect size. To investigate this, approximations of the effect size were calculated by dividing the mean REE by the mean FFM as discussed above (12) . These values were used in the analysis as substitutes for the 2 studies that did not directly provide the REE/FFM estimate. The SDs were then calculated by using the method recommended by Whitehead (18) , in which a pooled variance is calculated for all the studies with available values, and this value is then used to calculate the individual variance of the studies with missing values.
Third, influence analyses were used to investigate the sensitivity of the estimates to individual studies. For the classical and Bayesian random-effects models, sensitivity to individual studies was assessed by excluding and then replacing one study at a time and recalculating the mean difference and 95% CI (in the classical analysis, CI ҃ confidence interval; in the Bayesian analysis, CI ҃ credible interval) and the estimate of the betweenstudy variance or heterogeneity ( 2 ) and 95% CI for the Bayesian analysis (16) .
RESULTS
Seventy-three studies were identified in the initial search. Seven studies were conducted in children and were excluded on that basis (30 -36) . Two studies were excluded because the measures were not fasting or standardized (37, 38) , and 6 studies were excluded because body composition was either not assessed or not reported (39 -44) . Thus, 58 studies remained for consideration in the analysis (3, 4, 8, 9, 11, . Of these 58 studies, 32 included an HIV-negative control group, and they were considered for the primary analysis. Twenty-six of these 32 studies provided enough information for calculation of the crude effect estimate, and the inclusion of both an estimate and SD or SE allowed formal statistical analysis of 24 studies. When data for the HIV-positive group were presented only in subsets, either the asymptomatic, the weight-stable, or the HIV as opposed to the AIDS group was used for the primary analysis, and the additional subsets were used in the mixed indirect comparison estimate for which 37 studies were included and in the subgroup comparisons for which 30 studies were available. Authors of the 58 studies initially considered were contacted to ascertain whether they would provide either their original data for calculations of summary statistics or the summary statistics if the raw data were not provided in their reports. Individual data were available for 21 studies, 9 of which included a control group; it is important that individual data or summary estimates were provided for all studies that included subjects with lipodystrophy. Relevant details of all the studies conducted in adults are summarized elsewhere (see Appendix A under "Supplemental data" in the current issue at www.ajcn.org).
The mean effect size and 95% CIs for the difference between 785 HIV-positive subjects and 403 healthy control subjects-11.02 kJ/kg FFM (95% CI: 8.03, 14.01)-was obtained by using the method of Gotzsche (12), and those findings indicated that overall REE was significantly higher in HIV-positive subjects than in healthy control subjects. The means and sample sizes for the studies included in this analysis are shown in Table 1 .
The forest plot in Figure 1 shows each study's effect estimate and 95% CI, as well as the overall estimate for the DerSimonian and Laird random-effects primary analysis comparing the HIVpositive subjects and the control subjects. Means, SDs, and sample sizes are shown in Table 1 . The mean difference estimates and 95% CIs (or credible intervals for the Bayesian analyses) for the fixed-and random-effects models for the traditional and Bayesian analyses are shown in Table 2 . All analyses indicated that REE/FFM was significantly higher in HIV-positive subjects than in healthy control subjects.
For the random-effects models, the between-study variance ( 2 ) is shown along with the overall mean difference estimates. The 2 is inflated in the Bayesian models on the basis of the normal distribution and, to a lesser extent, by using the t distribution with the df modeled as an unknown parameter. Therefore, the estimate based on the t distribution with 4 df is used for comparison.
In this analysis, the informed prior distribution was similar to the data set incorporated in the likelihood and did not alter the posterior distribution (Table 2 ). In addition, the use of uniform prior distributions on , instead of the gamma prior distribution, resulted in similar estimates for the random-effects model, which suggests that the estimates were not sensitive to the distribution of the prior distribution (20) ( Table 2 ).
The use of the random-effects classical estimate of the overall mean difference (11.93 kJ/kg) and multiplication of that number by the mean FFM in the HIV-positive groups (53 kg) gives a daily difference in energy expenditure between HIV-positive and control subjects of Ȃ630 kJ (classical estimate) or Ȃ661 kJ [Bayesian random-effects estimate based on the t distribution (12.47 kJ/kg)]. This difference reflects an elevation in REE of Ȃ9% when the mean REE/FFM for HIV-positive subjects is divided by the REE/FFM for control subjects.
By using the pooled individual-subject dataset, REE in HIVpositive subjects (n ҃ 587) was significantly higher than that in control subjects (n ҃ 189) after adjustment for FFM (7229 and 6729 kJ/kg, respectively; P 0.001) by analysis of covariance (using the general linear model). Similarly, after adjustment for the study site, the elevation remained significantly (P 0.001) different between HIV-positive subjects (n ҃ 420; 7036 kJ/kg) and control subjects (6452 kJ/kg). These differences represent elevations of Ȃ7% and 9%, respectively, and are consistent with the meta-analysis values.
Assessment and exploration of heterogeneity
The test for heterogeneity was significant ( 2 ҃ 88.73, df ҃ 23; P 0.001), and the proportion of variability in the mean difference due to heterogeneity rather than to sampling error (I 2 ) was 74%. Forest plots of the various subgroupings are shown in Figure 2 . Within the HIV-positive subgroups, there was a trend toward higher REE/FFM in the symptomatic subjects than in the weight-stable subjects (P ҃ 0.079). Differences in REE/FFM between the weight-losing (P ҃ 0.590) and lipodystrophy (P ҃ 0.976) groups and the healthy control subjects were not significant. All HIV subgroups showed significantly higher REE/FFM than was seen in the control subjects: symptomatic subjects, P ҃ 0.012; weight-losing subjects, P ҃ 0.020l; subjects with lipodystrophy, P 0.001; and weight-stable subjects, P 0.001). Heterogeneity is evident in all subgroup comparisons (P 0.001) except that between weight-losing and weight-stable subjects (P ҃ 0.212). The mixed indirect comparison model (Table  3) shows that REE/FFM is significantly higher in all HIV subgroups than in the healthy control subjects and, in addition, that symptomatic subjects have significantly higher REE/FFM than do both the healthy control subjects and the other HIV subgroups.
The slope coefficients and intercepts of the metaregression analyses are shown in Table 4 . Lipodystrophy, method of bodycomposition measurement, subject age, and HAART usage in the HIV-positive group were unable to explain the heterogeneity by using metaregression in either a classical or Bayesian framework, as indicated by the 95% CIs (as confidence intervals and credible intervals, respectively) and P values of the slope coefficients.
Data were available from only 2 studies that included groups of HIV-positive subjects without lipodystrophy who were receiving and not receiving HAART. Our previous research (87) found REE/FFM in 32 subjects taking HAART to be 9.5 kJ/kg (95% CI: Ҁ21.51, 2.51) lower than that in 8 subjects not taking HAART, whereas Kosmiski et al (8) found that REE/FFM in 13 subjects taking HAART was 8.79 kJ/kg (95% CI: Ҁ2.21, 19.78) higher than that in 5 subjects not taking HAART, which led to an overall mean difference, combining these 2 studies, of Ҁ0.19 kJ/kg (95% CI: Ҁ18.11, 17.73). As a preliminary analysis, the 24 studies for the main analysis were split into 2 separate groups (5 studies in which all subjects were using HAART and 19 studies in which HIV-positive subjects were not using HAART); the studies in which subjects were using HAART had an overall mean difference in REE of 15.10 kJ/kg FFM compared with healthy controls, whereas the studies in which the HIV-positive subjects were not using HAART showed a mean difference of 11.02 kJ/kg FFM, which equates to an estimated difference of 216 kJ/d. (93) 137 Ȁ 13 [8] 111 Ȁ 11 [9] 1 All values are x Ȁ SD; n in brackets.
2 Measured in kJ per kg fat-free mass. 3 Data were pooled from 2 studies with the same control group. 4 A variance estimate was not available for these studies, which are included in the crude analysis and sensitivity analysis only. 5 Estimates were based on raw data provided by the authors of these 2 publications; the SD for the control group is the pooled SD, because data for control subjects were not available.
Publication bias
The funnel plot (Figure 3) shows both an overestimation and underestimation of the mean effect size, with the results in 10 studies clearly greater than the mean and those in another 10 studies below the mean; 4 studies fall virtually on the mean. There is some evidence of a "tunnel" or gap separating the outlying study by Kotler et al (3) . The 2 studies around the line of no difference between the groups both have a relatively small sample size, which indicates that nonsignificant studies with small sample sizes are published. The formal tests for publication bias-the tests of Egger et al (bias: ␣ ҃ Ҁ0.45, t ҃ Ҁ0.41; P ҃ 0.686) and Begg and Mazumdar (z ҃ 0.32, P ҃ 0.747)-were not significant. Visually, this finding is supported by presentation of the funnel plot of Begg and Mazumdar (Figure 3) , which is symmetrical except for the outlying study by Kotler et al (3) . The trim and fill method suggested there were no missing studies and produced an unadjusted estimate, and that, again, suggests that there was no publication bias in this analysis.
Sensitivity analysis
The fixed-effect estimates provided in Table 2 were similar to the random-effects estimates obtained by using both the classical and Bayesian methods. The mean difference between studies was similar with the use of all models. The Bayesian randomeffects analysis using the t distribution on 4 df produced the lowest value for the heterogeneity parameter 2 and is therefore the preferred estimate.
The calculated pooled SD was 15.15 kJ/kg FFM. This value was substituted for the SD for the 2 studies included in the crude analysis for which a variance estimate was not available so that the study could be included in the primary analysis ( Table 1 ). The random-effects meta-analysis was redone with these additional studies included. The combined mean difference was 12.77 kJ/kg FFM (95% CI: 9.45, 16.10 kJ/kg FFM; z ҃ 7.53, P 0.001). This difference would represent a daily difference in energy expenditure of only 16 kJ (based on an average FFM in the HIV studies of 53 kg) when compared with the random-effect Bayesian estimate (Student's t distribution on 4 df).
The Bayesian analysis of the influence of individual studies is shown in Table 5 . The removal of the data from the 2002 study by Korach et al (82) produced the highest mean difference, and the removal of the data from the 2004 study by Crenn et al (93) produced the lowest estimate; this difference translated into a small change in daily energy expenditure (61 kJ/d based on the average FFM of 53 kg). The most substantial effect on the between-study variation ( 2 ), which decreased by 74% of the combined estimate value, was seen when the data from the study of Kotler et al (3) Crenn et al (mean 11.40 kJ/kg; 95% CI: 7.90, 14.90). The estimated difference in energy expenditure between the highest and lowest studies was small (82 kJ/d), and, once again, the data of Kotler et al contributed substantially to the between-study variation ( 2 ), with the 2 value dropping to 39.21 (78% of the combined estimate) on removal of this study.
DISCUSSION
The primary aim of this research was to identify an overall mean difference in REE between HIV-positive and healthy control subjects. Although there is substantial variation in the literature, the analyses presented show that overall REE/FFM is higher in HIV-positive subjects than in healthy controls by an estimated 630-661 kJ/d, or Ȃ9%. Secondary analyses suggest that subjects symptomatic for AIDS may contribute to the heterogeneity, but the number of studies including these subjects was too small to investigate in formal analyses using metaregression. The presence of lipodystrophy in the HIV-positive group, the method of body-composition measurement used, the use of HAART in the HIV-positive group, and the average age of the subjects were unable to explain the variation by metaregression.
Before the introduction of HAART, elevations of REE in HIV-positive subjects were postulated to be the result of increased cytokine activity, particularly during symptomatic disease (76) or weight loss (38) or the result of increased viral activity as indicated by HIV RNA viral loads (37, 63) . Research was conflicting, however, with some studies finding no relation between REE and cytokines (54) or viral load (65, 87) ; difficulties in measuring cytokine activity (38, 55) and inconsistencies in additional confounding variables in the viral load models may account for these discrepancies. Since the introduction of HAART, 2 main factors have been causally implicated in increasing REE in HIV-lipodystrophy and HAART use per se.
It it important that this study shows that REE/FFM is higher in HIV-positive subjects with lipodystrophy than in healthy control subjects, but there is no significant difference between HIVpositive subjects with lipodystrophy and weight-stable HIVpositive subjects without lipodystrophy. Differences in antiretroviral regimens, mean subject ages, and other patient factors that are related to lipodystrophy (6, 98) could not be considered in this subanalysis because of the small sample size. Definitions of lipodystrophy in the various studies differed, and the recent development of a case definition of lipodystrophy (99) may provide more homogeneous results in future research. The validity of bioelectrical impedance analysis in subjects with lipodystrophy has been challenged (100), and, again, the sample size did not allow a metaregression on the effect of body-composition measurement methods in the lipodystrophy studies alone.
Shevitz et al (37) reported that REE adjusted for FFM, age, CD4 cell count, and HIV RNA viral load was 339 kJ/d higher in HIV-positive subjects using HAART than in those not using HAART; this difference was significant. On the basis of the present meta-analysis, this difference was estimated to be 216 kJ/d between studies in which subjects were using HAART and those in which subjects were not using HAART. This difference was not significant in the metaregression, but only 5 studies included subjects with HAART, and further research may allow an update to this analysis and may show a significant effect. The results of the study by Shevitz et al (37) must be interpreted cautiously because the study protocol did not require subjects to be measured after an overnight fast. The 2 longitudinal studies that have provided data on changes in REE with the introduction of protease inhibitors found no significant changes in REE over a median of 62 d (67) or 4.8 mo (82); longer-term data with adjustment for body-composition measurement method may be required to ascertain whether antiretroviral therapy per se affects REE.
Both classical and Bayesian methods of analysis were included in this meta-analysis. Bayesian approaches overcome the 2 main criticisms of classical random-effects analysis, because heavier-tailed t distributions can be used to avoid the normality assumption (10) , and all uncertainty is modeled in the estimate of the mean difference (18, 101) . The use of the t distribution in this analysis suggests that the between-study variation, 2 , was sensitive to the normality assumption and that it supported the use of the t distribution estimates in this case. Formal tests of normality in meta-analysis rely on large sample sizes and hence were not conducted in this analysis (102) .
There is some evidence that the initial study of Kotler et al (3) is an outlier, because the extreme effect size of that study accounted for Ȃ25% of the between-study variation ( 2 ), although the effect on the mean difference is not clinically significant. Their study was 1 of 2 included in which REE was not measured after an overnight fast but instead after a standardized protocol; however, the available evidence suggests this would increase rather than decrease REE/FFM (11) and thus is unlikely to explain the extreme nature of this result. Although the tests for publication bias were not significant, these tests have low power (15) , and the extreme nature of the effect size of the study by Kotler et al may indicate there is some bias in publishing studies showing that REE is lower in HIV-positive subjects. The visual inspection should be interpreted with caution because the sample size is small (15) , and further data are necessary to ascertain whether the data from the study of Kotler et al provided evidence of publication bias.
Analysis of covariance-adjusted estimates are the correct way to express the relation between REE and FFM because they avoid the mathematical artifacts associated with non-zero intercepts when REE is divided by FFM (23) . Although several authors have acknowledged this error (53, 66, 85, 87) , the unadjusted estimate (REE/FFM) was more common and was therefore used for this analysis. An ancillary analysis of covariance was conducted on the available individual data, and it supported the findings of this meta-analysis. Fat mass (87) , waist-to-hip ratio (8) , HIV RNA viral load (37, 63) , CD4 cell count (37), malabsorption (66) , and the use of antiretrovirals (37) have also been shown to be associated with REE in HIV-positive subjects; none of these factors could be incorporated into the current analysis because of inadequate data. Age (103) , sex (104), dietary intakes (2), smoking status (105) , and physical activity level (106) have all been shown to affect REE in healthy subjects, but of these only age could be considered in the present analysis.
The subgroup analyses must be interpreted with caution because multiple comparisons were not adjusted for in the Forest plots, and the incorporation of single-arm studies in a mixed indirect comparison can provide a guide only to the results that could be expected from a direct comparison. Nevertheless, these analyses provide hypotheses for future research and a meaningful way to use the data when data from only one group of interest are available or when sample sizes are too small for formal analysis using metaregression, or both.
The decision to exclude studies with nonstandardized postprandial protocols resulted in the exclusion of 2 of the largest published studies (37, 38) , but the available literature shows that diet-induced thermogenesis is altered in HIV infection (11) , and estimates from these studies would have been influenced by this alteration. Moreover, these studies did not have a healthy control group and would not have been included in the primary analysis.
In conclusion, this meta-analysis shows that REE/FFM is significantly higher in HIV-positive subjects than in healthy control subjects. Within the HIV-positive population, there is evidence that persons with symptomatic infection have significantly higher REE/FFM than do other HIV-positive persons; however, further studies are required to confirm these subgroup analyses. Additional studies may also provide further data from which to investigate the effect of HAART on REE in HIV. The research published to date suggests that REE/FFM in persons with lipodystrophy does not differ significantly from that in other weightstable HIV-positive persons. 
